DaVita Inc. (NYSE:DVA) Shares Purchased by Promethos Capital LLC

Promethos Capital LLC raised its position in DaVita Inc. (NYSE:DVA) by 120.0% during the 2nd quarter, Holdings Channel.com reports. The firm owned 28,396 shares of the company’s stock after acquiring an additional 15,490 shares during the quarter. DaVita accounts for about 1.5% of Promethos Capital LLC’s investment portfolio, making the stock its 28th biggest position. Promethos Capital LLC’s holdings in DaVita were worth $3,935,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in DVA. Blue Trust Inc. increased its position in DaVita by 58.6% in the 2nd quarter. Blue Trust Inc. now owns 211 shares of the company’s stock valued at $29,000 after acquiring an additional 78 shares during the period. Wedmont Private Capital raised its stake in shares of DaVita by 6.0% during the second quarter. Wedmont Private Capital now owns 1,701 shares of the company’s stock valued at $241,000 after purchasing an additional 96 shares in the last quarter. First Trust Direct Indexing L.P. lifted its holdings in DaVita by 3.9% in the first quarter. First Trust Direct Indexing L.P. now owns 2,590 shares of the company’s stock worth $358,000 after purchasing an additional 98 shares during the period. Quent Capital LLC grew its position in DaVita by 21.0% in the 1st quarter. Quent Capital LLC now owns 581 shares of the company’s stock valued at $80,000 after buying an additional 101 shares in the last quarter. Finally, GAMMA Investing LLC increased its stake in DaVita by 18.8% during the 1st quarter. GAMMA Investing LLC now owns 657 shares of the company’s stock valued at $91,000 after buying an additional 104 shares during the period. Institutional investors own 90.12% of the company’s stock.

Insider Buying and Selling

In other DaVita news, insider Kathleen Alyce Waters sold 7,857 shares of the business’s stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $146.21, for a total transaction of $1,148,771.97. Following the sale, the insider now directly owns 83,011 shares of the company’s stock, valued at approximately $12,137,038.31. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other DaVita news, insider Kathleen Alyce Waters sold 7,857 shares of the firm’s stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $146.21, for a total transaction of $1,148,771.97. Following the completion of the sale, the insider now directly owns 83,011 shares in the company, valued at approximately $12,137,038.31. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Javier Rodriguez sold 50,000 shares of the company’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $165.05, for a total value of $8,252,500.00. Following the completion of the transaction, the chief executive officer now owns 837,835 shares in the company, valued at approximately $138,284,666.75. The disclosure for this sale can be found here. In the last 90 days, insiders sold 173,482 shares of company stock valued at $27,387,069. Company insiders own 2.00% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the stock. UBS Group raised their price objective on shares of DaVita from $169.00 to $175.00 and gave the company a “buy” rating in a research note on Thursday, August 8th. Truist Financial boosted their price objective on DaVita from $150.00 to $165.00 and gave the stock a “hold” rating in a research note on Tuesday, August 20th. Bank of America raised their target price on DaVita from $139.00 to $145.00 and gave the company an “underperform” rating in a research note on Wednesday, August 7th. StockNews.com cut shares of DaVita from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 8th. Finally, TD Cowen raised their price objective on shares of DaVita from $139.00 to $150.00 and gave the company a “hold” rating in a research report on Wednesday, July 24th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $157.00.

DaVita Stock Down 0.0 %

Shares of DaVita stock opened at $163.14 on Friday. DaVita Inc. has a 12-month low of $71.51 and a 12-month high of $166.04. The firm has a market capitalization of $14.31 billion, a PE ratio of 18.54, a price-to-earnings-growth ratio of 0.95 and a beta of 0.87. The company has a quick ratio of 1.12, a current ratio of 1.16 and a debt-to-equity ratio of 9.94. The stock’s fifty day moving average is $146.73 and its 200-day moving average is $140.69.

DaVita (NYSE:DVA) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $2.59 EPS for the quarter, beating analysts’ consensus estimates of $2.47 by $0.12. The company had revenue of $3.19 billion during the quarter, compared to analyst estimates of $3.15 billion. DaVita had a net margin of 6.86% and a return on equity of 77.00%. The business’s quarterly revenue was up 6.2% on a year-over-year basis. During the same period in the prior year, the firm earned $2.08 earnings per share. Equities analysts anticipate that DaVita Inc. will post 9.99 earnings per share for the current year.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.